Inhibrx Q3 Loss Widens

November 13, 2026 — 04:19 pm EST

Written by RTTNews.com for RTTNews

(RTTNews) - Inhibrx Biosciences, Inc. (INBX), a clinical-stage biopharmaceutical, on Friday reported a wider third-quarter loss, reflecting higher general and administrative expenses.

The company posted a net loss of $38.7 million, or $2.46 per share, compared to a net loss of $35.3 million, or $2.28 per share, in the year-ago quarter.

Revenue was $2 million, compared to no revenue in the prior-year period, reflecting an upfront payment under a non-exclusive patent license agreement with Pfizer Inc.

Research and development expenses declined to $26 million from $28.5 million, while general and administrative expenses increased to $7.8 million from $5.3 million.

Total other expense rose to $7 million from $1.4 million, primarily due to higher interest expense on outstanding borrowings.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Inhibrx Q3 Loss Widens

Tags

Latest Articles